Simone Braig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Simone Braig has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Angelika M. Vollmar
Department of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-University of Munich (LMU), Butenandtstrasse 5-13, Munich, D-81377, Germany
2 shared publicationsOlga Nagło
Department of Pharmaceutical Biology, Ludwig Maximilian University of Munich
2 shared publicationsStefan Zahler
Department of Pharmaceutical Biology, Ludwig Maximilian University of Munich
2 shared publications- Andreas Koeberle
Michael Popp Institute and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck 6020, Austria
1 shared publication Behnaz A. Abhari
Institute for Experimental Cancer Research in Pediatrics, J.W. Goethe University Hospital Frankfurt, Frankfurt a. M., Germany
1 shared publication- Binje Vick
Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Munich, German Research Center for Environmental Health, Munich, Germany
1 shared publication
Latest Publications
- Open Access
- 18 June 2019
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 5 (7) , 1170-1178
Neocarzilin A Is a Potent Inhibitor of Cancer Cell Motility Targeting VAT-1 Controlled Pathways
The natural product neocarzilin A (NCA) was discovered decades ago, and despite its potent cytotoxic effects no mode of action studies have been performed up to date. Synthesis of neocarzilins A, B, and C and a stereoisomer of NCA provided insights into structural preferences as well as access to probes for functional studies. NCA turned out to be the most active member and was not only effective against cell proliferation but also migration, a novel and so far overlooked activity. To decipher the molecular mode of action, we applied chemical proteomics for target discovery and revealed that NCA targets cancer cell migration via irreversible binding to the largely uncharacterized synaptic vesicle membrane protein VAT-1. A corresponding knockout of the protein confirmed the phenotype, and pull-down studies showed the interaction with an intricate network of key migration mediators such as Talin-1. Overall, we introduce VAT-1 as a promising novel target for the development of selective migration inhibitors with the perspective to limit toxicity in the absence of antiproliferative effects.
- 18 June 2019
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 5 (7) , 1170-1178
Open AccessNeocarzilin A Is a Potent Inhibitor of Cancer Cell Motility Targeting VAT-1 Controlled Pathways
The natural product neocarzilin A (NCA) was discovered decades ago, and despite its potent cytotoxic effects no mode of action studies have been performed up to date. Synthesis of neocarzilins A, B, and C and a stereoisomer of NCA provided insights into structural preferences as well as access to probes for functional studies. NCA turned out to be the most active member and was not only effective against cell proliferation but also migration, a novel and so far overlooked activity. To decipher the molecular mode of action, we applied chemical proteomics for target discovery and revealed that NCA targets cancer cell migration via irreversible binding to the largely uncharacterized synaptic vesicle membrane protein VAT-1. A corresponding knockout of the protein confirmed the phenotype, and pull-down studies showed the interaction with an intricate network of key migration mediators such as Talin-1. Overall, we introduce VAT-1 as a promising novel target for the development of selective migration inhibitors with the perspective to limit toxicity in the absence of antiproliferative effects.
- 1 November 2018
- Published by Elsevier in Biotechnology Advances
- Vol. 36 (6) , 1724-1729
Chemical genetics in tumor lipogenesis
- 1 November 2018
- Published by Elsevier in Biotechnology Advances
- Vol. 36 (6) , 1724-1729
Chemical genetics in tumor lipogenesis
- Open Access
- 11 October 2018
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (3) , 546-555
Targeting the endoplasmic reticulum-mitochondria interface sensitizes leukemia cells to cytostatics
Combination chemotherapy has proved to be a favorable strategy to treat acute leukemia. However, the introduction of novel compounds remains challenging and is hindered by a lack of understanding their mechanistic interaction with established drugs. In the present study, we demonstrate a highly increased response of various acute leukemia cell lines, drug resistant cells and patient-derived xenograft cells by combining the recently introduced protein disulfide isomerase inhibitor PS89 with cytostatics. In leukemic cells, a proteomics based target fishing approach disclosed that PS89 impacts a whole network of endoplasmic reticulum homeostasis proteins. We elucidate that the strong apoptosis induction in combination with cytostatics is orchestrated by the PS89 target B-cell receptor-associated protein 31, which transduces apoptosis signals at the ER-mitochondria interface. Activation of caspase-8 and cleavage of BAP31 stimulate a pro-apoptotic crosstalk including endoplasmic reticulum calcium release and increased reactive oxygen species levels resulting in amplification of mitochondrial apoptosis. This study promotes PS89 as a novel chemosensitizing agent for acute leukemia treatment and uncovers that targeting the endoplasmic reticulum-mitochondria network of cell death is a promising approach in combination therapy.
- 11 October 2018
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (3) , 546-555
Open AccessTargeting the endoplasmic reticulum-mitochondria interface sensitizes leukemia cells to cytostatics
Combination chemotherapy has proved to be a favorable strategy to treat acute leukemia. However, the introduction of novel compounds remains challenging and is hindered by a lack of understanding their mechanistic interaction with established drugs. In the present study, we demonstrate a highly increased response of various acute leukemia cell lines, drug resistant cells and patient-derived xenograft cells by combining the recently introduced protein disulfide isomerase inhibitor PS89 with cytostatics. In leukemic cells, a proteomics based target fishing approach disclosed that PS89 impacts a whole network of endoplasmic reticulum homeostasis proteins. We elucidate that the strong apoptosis induction in combination with cytostatics is orchestrated by the PS89 target B-cell receptor-associated protein 31, which transduces apoptosis signals at the ER-mitochondria interface. Activation of caspase-8 and cleavage of BAP31 stimulate a pro-apoptotic crosstalk including endoplasmic reticulum calcium release and increased reactive oxygen species levels resulting in amplification of mitochondrial apoptosis. This study promotes PS89 as a novel chemosensitizing agent for acute leukemia treatment and uncovers that targeting the endoplasmic reticulum-mitochondria network of cell death is a promising approach in combination therapy.
- Open Access
- 7 November 2017
- Published by Springer Nature in British Journal of Cancer
- Vol. 118 (1) , 43-51
Targeting de novo lipogenesis as a novel approach in anti-cancer therapy
Although altered membrane physiology has been discussed within the context of cancer, targeting membrane characteristics by drugs being an attractive therapeutic strategy has received little attention so far. Various acetyl-CoA carboxylase 1 (ACC1), and fatty acid synthase (FASN) inhibitors (like Soraphen A and Cerulenin) as well as genetic knockdown approaches were employed to study the effects of disturbed phospholipid composition on membrane properties and its functional impact on cancer progression. By using state-of-the-art methodologies such as LC-MS/MS, optical tweezers measurements of giant plasma membrane vesicles and fluorescence recovery after photobleaching analysis, membrane characteristics were examined. Confocal laser scanning microscopy, proximity ligation assays, immunoblotting as well as migration, invasion and proliferation experiments unravelled the functional relevance of membrane properties in vitro and in vivo. By disturbing the deformability and lateral fluidity of cellular membranes, the dimerisation, localisation and recycling of cancer-relevant transmembrane receptors is compromised. Consequently, impaired activation of growth factor receptor signalling cascades results in abrogated tumour growth and metastasis in different in vitro and in vivo models. This study highlights the field of membrane properties as a promising druggable cellular target representing an innovative strategy for development of anti-cancer agents.
- 7 November 2017
- Published by Springer Nature in British Journal of Cancer
- Vol. 118 (1) , 43-51
Open AccessTargeting de novo lipogenesis as a novel approach in anti-cancer therapy
Although altered membrane physiology has been discussed within the context of cancer, targeting membrane characteristics by drugs being an attractive therapeutic strategy has received little attention so far. Various acetyl-CoA carboxylase 1 (ACC1), and fatty acid synthase (FASN) inhibitors (like Soraphen A and Cerulenin) as well as genetic knockdown approaches were employed to study the effects of disturbed phospholipid composition on membrane properties and its functional impact on cancer progression. By using state-of-the-art methodologies such as LC-MS/MS, optical tweezers measurements of giant plasma membrane vesicles and fluorescence recovery after photobleaching analysis, membrane characteristics were examined. Confocal laser scanning microscopy, proximity ligation assays, immunoblotting as well as migration, invasion and proliferation experiments unravelled the functional relevance of membrane properties in vitro and in vivo. By disturbing the deformability and lateral fluidity of cellular membranes, the dimerisation, localisation and recycling of cancer-relevant transmembrane receptors is compromised. Consequently, impaired activation of growth factor receptor signalling cascades results in abrogated tumour growth and metastasis in different in vitro and in vivo models. This study highlights the field of membrane properties as a promising druggable cellular target representing an innovative strategy for development of anti-cancer agents.
- 1 September 2014
- Published by Elsevier in Biochemical Pharmacology
- Vol. 91 (2) , 157-167
The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer
- 1 September 2014
- Published by Elsevier in Biochemical Pharmacology
- Vol. 91 (2) , 157-167
The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer